Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas

Experimental and Molecular Pathology
Yuwen XieFeng Li

Abstract

Soft tissue sarcomas (STSs) are comparatively rare malignant tumors with poor prognosis. STSs predominantly arise from mesenchymal differentiation. MicroRNA-34b/c, the transcriptional targets of tumor suppressor p53, possesses tumor suppressing property. Hypermethylation of miR-34b/c has been associated with tumorigenesis and the progression of various cancers. To determine whether aberrant miR-34b/c methylation occurs in STSs, we quantitatively evaluated the methylation level of miR-34b/c in 57 STS samples and 20 cases of peripheral blood from healthy volunteers serving as normal controls by using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. We found that miRNA34b/c is more frequently methylated in STSs (0.157±0.028) than in normal controls (0.098±0.012, p=0.038). Furthermore, the methylation levels of CpG_1.2.3, CpG_4.5.6.7, and CpG_11.12.13 of miR-34b/c were significantly higher in the STS group than in the normal control group (p<0.001). No significant differences in the methylation levels within miR-34b/c were observed between specific reciprocal translocations in STSs and nonspecific reciprocal translocations in STSs (0.146±0.039 vs. 0.168±0.035, p>0.05). The methylation levels of miR-34b/...Continue Reading

References

Aug 23, 2008·Cell Cycle·Dmitri LodyginHeiko Hermeking
Feb 4, 2009·Virchows Archiv : an International Journal of Pathology·Fredrik MertensNils Mandahl
Dec 1, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Stephen E HawesHubert Vesselle
Mar 5, 2010·Cleveland Clinic Journal of Medicine·Hakan IlaslanMurali Sundaram
Mar 6, 2010·Nucleic Acids Research·Asli Petra BauerRalf Wagner
Mar 10, 2011·Nature Medicine·Manuel Rodríguez-Paredes, Manel Esteller
Nov 4, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Norimitsu TanakaShinichiro Miyoshi
Dec 1, 2011·Epigenomics·Kwan Yeung WongChor Sang Chim
Aug 14, 2012·Child Development·Moshe Szyf, Johanna Bick
Sep 21, 2012·Journal of Hematology & Oncology·Sanchita RoyFazlul H Sarkar
Jan 22, 2013·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Francesc Piferrer
Apr 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hsuan-Ying HuangChien-Feng Li
Jul 24, 2013·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Moshe Szyf
Oct 17, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ernest NadalDavid G Beer
Oct 29, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Carlos G PenalozaZahra Zakeri
Nov 20, 2013·The Journal of Biological Chemistry·Yarui DiaoZhenguo Wu
Nov 23, 2013·Journal of Experimental & Clinical Cancer Research : CR·Xiaolan LiuYa Cao
Jan 3, 2014·Cancer·Simone HettmerDavid Malkin
Feb 20, 2014·International Journal of Evolutionary Biology·Annalisa Varriale
Feb 25, 2014·Journal of Translational Medicine·Lu Qian WangChor Sang Chim
Mar 4, 2014·International Journal of Oncology·Sebastian WolfRoland Kappler
Apr 18, 2014·Journal of Molecular Cell Biology·Jun-Ming LiaoHua Lu
May 9, 2014·Journal of Clinical Pathology·Ho Yin NgChor Sang Chim
May 13, 2014·Journal of Molecular Cell Biology·Matjaz RokavecHeiko Hermeking
Jun 3, 2014·Molecular Cancer·Ding-Guo ZhangDong-Sheng Pei
Jul 1, 2014·World Journal of Gastroenterology : WJG·Sumadi Lukman Anwar, Ulrich Lehmann
Jul 6, 2014·Mediators of Inflammation·Amit KishoreMartin Petrek

❮ Previous
Next ❯

Citations

Feb 6, 2016·International Journal of Molecular Sciences·Bhairavi SrinageshwarJulien Rossignol
Feb 27, 2020·Pharmaceutics·Surasa NagachintaMaria de la Fuente
Aug 26, 2017·Endocrine·Hamidreza MaroofAlfred K Lam
Feb 12, 2017·Pharmacology & Therapeutics·Subhankar Biswas, C Mallikarjuna Rao
Jul 22, 2021·Current Problems in Cancer·Geraldine O'Sullivan CoyneAlice P Chen
May 2, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Mohammad Hasan SoheilifarMohammad Reza Motie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.